Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TACR1 | P25103 | 5/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287872 | 1.00 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| SCHEMBL4292821 | 1.00 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| SCHEMBL4287876 | 1.00 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| SCHEMBL4287875 | 1.00 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| Bromide SCHEMBL1593624 | 0.99 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| Bromide SCHEMBL1593628 | 0.99 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| Bromide SCHEMBL1593626 | 0.99 | NPY5R (0.48) | NPY5RKDM4EKDM1AMAOAMAOB | |
| Oxalic Acid SCHEMBL1593706 | 0.94 | KMT2A (0.51) | NPY5RKDM4EKDM1AMAOAMAOB | |
| Oxalic Acid SCHEMBL1593708 | 0.94 | KMT2A (0.51) | NPY5RKDM4EKDM1AMAOAMAOB | |
| Oxalic Acid SCHEMBL1593705 | 0.94 | KMT2A (0.51) | NPY5RKDM4EKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1119543-B1 | N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1119543-A1 | N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6201025-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2000020376-A1 | N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | NPY5R 2/4885KDM4E 2037/4885KDM1A 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.